Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a chronic hematological malignancy with heterogeneous clinical outcome.
1 Some patients will not need treatment for years, whereas others will progress rapidly. Multiple novel prognostic factors with respect to clinical behavior were recently identified. Several studies revised the prognostic value of existing markers, proving that besides the stage of disease, serological markers, expression of zeta protein-associated protein-70, expression of CD38, the mutational status of variable part of the immunoglobulin heavy chain gene (IgVH) as well as the genomic aberrations represent the strongest indicators of clinical behavior. 1 The receptor for hyaluronic acid-mediated motility (RHAMM) protein shows a differential expression pattern in healthy tissue and is overexpressed in many cancers and hematological malignancies. [2] [3] [4] [5] [6] CD44, another hyaluronic acid receptor, as well as its soluble form was identified in B-CLL as negative prognostic markers. 7 Moreover, elevated levels of CD44 correlated with the proliferative potential of CLL. 8 Both, CD44 and RHAMM are required for angiogenesis through the interaction with hyaluronic acid receptor. 9 Therefore, we tested whether RHAMM is correlated with proliferation in B-CLL and whether its expression possesses prognostic value in B-CLL.
In an earlier report, we identified an enhanced RHAMM expression in B-CLL patients. 4 Immunogenic Human Leukocyte Antigen-A2-restricted epitopes for RHAMM, eliciting T-cell responses cytotoxic responses in B-CLL patients, were found. We therefore proposed RHAMM as a novel immunogenic leukemia-associated antigen (LAA) in B-CLL. 4 As the expression of immunogenic LAA might influence the clinical outcome by the means of immune reactions, we further characterized the expression of RHAMM-specific T cells in B-CLL patients. The cytotoxic potential of RHAMM-specific T cells was assessed in chromium (Cr-51) release assays against cells bearing RHAMM-derived epitope as well as against CLL cells expressing RHAMM.
We further speculated whether the RHAMM expression is associated with naturally occurring RHAMM-reactive T cells. Moreover, we questioned whether the RHAMM-specific CD8 þ T cells contribute to the elimination of RHAMM-positive CLL cells resulting in a better survival.
Materials and methods

Cell samples
Samples were taken from 72 untreated B-CLL patients at the Department of Internal Medicine III at the University of Ulm and at the Department of Hematooncology at the Medical University of Lublin. Peripheral blood samples were also taken from 10 healthy volunteers (HVs; age range: 25-75 years, mean: 56 years; six men and four women). This study was approved by the Local Ethics Committee (No. KE-025411/2006 
Cell preparation, RNA isolation and molecular genetics
Mononuclear cells were isolated from peripheral blood (PBMC) as well as bone marrow (BM) aspirates by Ficoll (Biochrom AG, Berlin, Germany) density gradient centrifugation. The viability of obtained cells was always 495% as determined by trypan blue exclusion test. Viable cells were quantified in a Neubauer chamber (Zeiss, Oberkochen, Germany) and stored in liquid nitrogen for functional assays. Ten million cells were pelleted and stored at À80 1C for RNA isolation. Total RNA was isolated using TRIzol reagent (Sigma-Aldrich, Munich, Germany) and reverse transcribed using the AMV Reverse Transcription Kit (Roche, Mannheim, Germany). Molecular genetic characterization (genomic aberrations by fluorescent in situ hybridization and IgVH status by sequencing) as well as zeta proteinassociated protein-70 and CD38 analyses were performed as described earlier. [10] [11] [12] Reverse transcriptase polymerase chain reaction of RHAMM Reverse transcriptase PCR for RHAMM was performed as described earlier. 4 In all RHAMM positive ( þ ) CLL patients, we observed two PCR products representing both splicing variants of RHAMM, that is, transcripts lacking exon4 (RHAMM
Àexon4
) and full length transcripts (RHAMM   FL   ) . These PCR products were quantitated using fluorescence capillary electrophoresis (DNA 1000 chip using Agilent Bioanalyzer 2100, Agilent, USA). The amounts of RHAMM Àexon4 and RHAMM FL products were assessed and the RHAMM Àexon4 / RHAMM FL ratio was calculated. An example of the evaluation of splicing variants using fluorescence capillary electrophoresis is shown in Supplementary Figure 1 .
Quantitative 'real time' reverse transcriptase polymerase chain reaction of RHAMM Quantitative real-time reverse transcriptase PCR for RHAMM was performed using the Light Cycler SYBR Green I technology according to the manufacturer's protocol (Roche) and as described in detail elsewhere. 4 RHAMM expression was normalized to TATA-binding protein (TBP) expression using the difference in cycle threshold (dCt) method.
Peptides
On the basis of our earlier studies, 4 the RHAMM-derived Human Leukocyte Antigen-A2-restricted CD8 þ T cell epitope R3 (pos. 165-173; ILSLELMKL) represents an immunogenic peptide in B-CLL and was therefore chosen for further analysis. MAGE-derived peptide (MAGE-3) served as a negative control. All peptides were synthesized by the Thermo Electron Corporation (Ulm, Germany) with a minimum of 95% purity as measured by high performance liquid chromatography.
Mixed lymphocyte peptide culture and interferon-g ELISpot assays
Peripheral blood mononuclear cells from Human Leukocyte Antigen-A2-positive B-CLL patients were thawed with a yield of 495% viable cells and subsequently left for a 24 h resting period in the culture medium containing RPMI 1640 supplemented with 10% AB serum (Sigma-Aldrich). On the next day cells were counted, seeded in a 6-well plate and pulsed with R3 or irrelevant melanoma antigen (MAGE)-3 peptide at a concentration of 20 mg/ml or without peptide as a negative control. The MLPC was supplemented with 10 U/ml interleukin (IL-2) (recombinant human interleukin-2, Sigma-Aldrich) and 20 ng/ml IL-7 (recombinant human interleukin-7, Strathmann Biotec AG, Hamburg, Germany) on day þ 1. On day þ 7 MLPC cells were harvested and evaluated for specific cytotoxicity in an ELISpot assay as described earlier. 4 ELISpot assays were performed as recommended by the Cancer Immunotherapy Monitoring Panel that our institution is a part of. 13 
FACS analysis of regulatory T cells
Peripheral blood mononuclear cells from B-CLL patients were thawed in RPMI 1640-containing DNAse (Sigma-Aldrich) to avoid the formation of cell aggregates, with a yield of 495% viable cells. Staining of 1 Â 10 6 cells for the surface antigens CD4, CD8 and CD25 was performed according to the manufacturers protocol (BD Biosciences, Mannheim, Germany). Thereafter cells were permeabilized, unspecific epitopes blocked with rat serum and cells were stained with anti-FOXP3 rat monoclonal antibody according to the manufacturer's protocol (eBiosciences, San Diego, CA, USA). After intracellular staining, cells were washed twice and CD4 þ cells analyzed for CrO 4 (Cr-51) for 2 h as described earlier. 2 After washing, labeled cells were incubated with pre-stimulated CD8-positive T cells at effectortarget ratios of 20:1 to 2.5:1 for 16 h at 37 1C. Radioactivity in the supernatant from all wells of round-bottomed 96-well plates (Becton Dickinson, Heidelberg, Germany) was measured by a gamma counter (PerkinElmer, Boston, MA, USA). The percentage of specific lysis was calculated as (Cr-51 release in the test well minus spontaneous Cr-51 release)/(maximum Cr-51 release minus spontaneous Cr-51 release).
Immunohistochemistry for the detection of RHAMM/ CD168, Ki-67 and CD40L protein expression in lymph nodes 
Cell culture with CD40L as well as stimulation of CLL cells with IL-4 and oligonucleotide CpG
Based on data from the literature 14 and our own results, 15 we stimulated magnetically separated CD19 þ from PBMC of five CLL patients as well as five HVs with 0.5 mg/ml CD40L (Alexis, San Diego, USA) as described earlier. 15 To assess whether RHAMM expression is associated solely with proliferation or with CD40L signaling, we stimulated CD19 þ from six high-risk CLL patients with 50 ng/ml IL-4 (R&D systems, Wiesbaden, Germany) and 2 mM oligonucleotide CpG (DSP30, TIBMolBiol, Berlin, Germany) for 4 days. After cell culture, mRNA was isolated using the mMACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
Statistical analysis
All results are presented as median values with range. The U Mann-Whitney test was used to evaluate the differences between subgroups of patients. The Kaplan-Meier test was used to evaluate the influence of RHAMM expression and mutational status on treatment-free survival (TFS) in different patients groups.
Results
Differential expression of RHAMM and RHAMM
Àexon4 /RHAMM FL splicing variants
To characterize RHAMM expression, 72 CLL patients were assessed using reverse transcriptase PCR. 
d). This overexpression is true for both RHAMM
Àexon4
/RHAMM FL splicing variants, as the ratio of the two variants showed no significant difference between mutated and unmutated CLL cases (1.21 vs 1.44, P ¼ 0.12).
Also, higher RHAMM/TBP expression was observed in highrisk CLL cases with del11q or del17p (0.048 vs 0.003 as compared with patients with normal karyotype, P ¼ 0.01). Patients with normal karyotype presented the lowest RHAMM expression both in quantative PCR and fluorescence capillary electrophoresis analyses. Interestingly, in all groups with cytogenetic aberrations, the RHAMM Àexon4 splicing variant was predominantly expressed, whereas in CLL with normal karyotype RHAMM FL form was highly expressed. However, no differences in the median ratios of the two splicing variants were observed. The expression of RHAMM and its splicing variants in CLL patients with different genomic aberrations are summarized in Figure 2 .
RHAMM/TBP expression tended to be higher in zeta proteinassociated protein-70 positive ( þ ) CLL patients (0.035, range: 0.0002-0.33 vs 0.026, range: 0.002-0.33, P ¼ 0.07) but no difference in RHAMM/TBP was observed between CD38 positive ( þ ) and CD38 negative (À) patients (0.03, range: 0.002-0.33 vs 0.03, range: 0.0006-0.32, respectively).
RHAMM as a prognostic factor
To investigate whether expression of RHAMM would correlate with prognostic subgroups of CLL patients, we measured expression of RHAMM in a group of IgVH mutated patients and compared it with a group of unmutated CLL cases that differed significantly in their TFS (86 vs 9.4 months, P ¼ 0.00001, Figure 3b) . Interestingly, CLL cases with a higher RHAMM expression (RHAMM/TBP ratio 40.027) showed a significantly shorter median TFS (14 vs 48.6 months, P ¼ 0.00019, Figure 3a) . Moreover, among IgVH mutated cases, RHAMM expression provided additional prognostic value and enabled to distinguish subgroup of patients with the longest TFS. In a Kaplan-Meier analysis, those patients who were IgVH mutated and expressed low amounts of RHAMM presented the longest TFS compared with all other groups of patients. The shortest TFS was observed in IgVH unmutated cases with a high RHAMM expression (Figure 3c ), thus confirming significance of RHAMM expression as additional prognostic value for CLL.
Expression of RHAMM correlates with proliferation of CLL cells
As the expression of RHAMM correlated with TFS in CLL patients, we wanted to test whether RHAMM was expressed in proliferating compartments of the CLL. As a proliferation marker, 16 we analyzed expression of Ki-67 antigen in LN samples of CLL patients. In addition, it has been shown earlier that CD40L can induce proliferation of CLL cells in vitro, 17 and therefore we also tested for levels of CD40L in these LN samples. We detected RHAMM protein in the proliferation centers of all infiltrated LN from CLL patients. Intriguingly, RHAMM positive cells co-localized with nuclear Ki-67 positivity as well as CD40L expression. Figure 4 paradigmatically shows two cases, one with a high Ki-67 proliferation index and CD40L positive cells and a second patient with a lower proliferative Ki-67 index and no expression of CD40L. Thus, in LN with a higher level of RHAMM protein we observed a higher Ki-67 index and a higher expression of CD40L. Interaction of the CLL cells with CD40L also has been suggested earlier to take place not only in LN but also in the BM.
14 Therefore, we measured expression of RHAMM in BM samples of CLL patients (n ¼ 5) and compared them with expression levels in PBMC (Figure 5a ). In line with the concept of the BM-harboring proliferating CLL cells and RHAMM to be associated with proliferating CLL cells, we found a significantly higher expression of RHAMM in the Table 1. (1.65, range: 0.81-2.46 vs 0.067, range: 0.015-0.143; P ¼ 0.008) (Figure 5b ). In contrast, no expression of RHAMM on magnetically separated CD19 þ B cells from five HVs was found after CD40L stimulation. To characterize whether RHAMM overexpression is associated solely with CD40L signaling or CD40L-driven proliferation, we stimulated six high-risk CLL patients with IL-4 and CpG that effectively induce proliferation in a CD40L-independent manner. After stimula- tion, RHAMM expression was slightly higher (median 0059, range: 0.048-0.98 vs 0.11, range: 0.047-0.152; P ¼ 0.17) (Figure 4c ). Of note, in three cases that proliferated to a higher extent in response to IL-4/CpG (two of them with del17p), RHAMM expression was enhanced 2.3 times (P ¼ 0.1), whereas in patients, that proliferated to a lesser extent, RHAMM expression was enhanced only 1.7 times (not significant). In summary, these results point to a role of CD40L in inducing RHAMM expression, which at least in part is associated with proliferation.
B-CLL patients harbor T cells specific for RHAMM
CLL cells are massively present in the immunological organs and specifically overexpress the LAA RHAMM. Therefore, it would be likely that these CLL patients harbor T cells that are specific for the LAA RHAMM. However, we expected the frequency of these T cells to be very low. We therefore pre-stimulated lymphocytes to amplify RHAMM-specific T cells for further functional analyses. Indeed, we were able to detect RHAMMspecific T cells in 11 of 12 CLL patients that secreted IFN-g in MLPC (Supplementary Figure 2) . Unexpectedly, the frequency of these T cells did not correlate neither with the expression of RHAMM nor with the mutational status or the stage of disease (data not shown). These RHAMM-specific T cells had cytotoxic potential to lyse cells pulsed with a RHAMM-derived epitope R3 and also CLL cells expressing RHAMM in Cr release assay (Figure 6a) . A high level of RHAMM-specific lysis occurred in pulsed T2 cells and CLL cells in contrast to unpulsed T2 cells or K562 (Figure 5a ). RHAMM-specific CD8 þ cells were able to lyse all CLL cells at effector/target (E/T) ratio of 20:1, 64% at E/T ratio of 10:1 and 12% at an E/T ratio of 5:1. Primed T lymphocytes were also able to lyse RHAMM pulsed T2 cells in 50% at an E/T ratio of 20:1, 45.6% at an E/T ratio of 10:1 and 12.6% at an E/T ratio of 5:1. To exclude NK-mediated lysis, MHC class I negative K562 cells were added. As a negative control, only 16% of unpulsed T2 cells were lysed at the highest E/T ratio of 20:1. RHAMM-specific T cells were unable to lyse T2 cells at lower ratios as well as K562 cells, hence proving specificity of the RHAMM-primed cytotoxic T cells.
As the expression of immunogenic tumor-associated antigens (TAA) might influence the clinical outcome by eliciting an immune response in cancer patients, we correlated the presence of RHAMM-specific T cells in B-CLL patients with their TFS. Interestingly, patients with higher numbers of RHAMM-specific T cells tended to a have longer TFS when compared with those with limited numbers of RHAMM-specific T cells (24 vs 8 months, P ¼ 0.3). Therefore, it is possible that T cells specific for the CLL-specific LAA RHAMM might have a protective effect in CLL patients. However, the protective immune effect of RHAMM-specific T cells might be hindered by an excess of regulatory T cells (Treg) in patients with B-CLL. Addressing this setting, we observed enhanced frequencies of Figure 6b ). The suppressive function of Treg against LAA RHAMM was confirmed by the inverse correlation of frequencies of RHAMM-specific CD8 þ T cells and Treg (r 2 ¼ À0.7, Po0.02, Figure 6c ).
Discussion
RHAMM expression has earlier been associated with worse prognosis in several tumor entities like multiple myeloma, breast cancer and colon carcinoma. [18] [19] [20] Therefore, we recently evaluated the influence RHAMM expression on the survival of acute myeloid leukemia patients using cDNA microarray technology. 21 However, in acute myeloid leukemia, RHAMM expression was associated with a trend towards prolonged survival. Increased expression of other TAA like G250/MN/CA-9 and PRAME significantly correlated with overall survival. Interestingly, subsequent analysis showed that enhanced expression of at least one TAA (including RHAMM) was of clinical benefit for acute myeloid leukemia patients, suggesting that tumor-specific effector T cells could mount an immune response against acute myeloid leukemia blasts. Conversely, here we found an increased RHAMM expression in CLL cases with negative prognostic factors such as zeta protein-associated protein-70, unmutated status of IgVH genes as well as highrisk CLL cases characterized by del17p or del11q. In addition, the expression of RHAMM was of prognostic value itself resulting in shorter TFS for cases with high RHAMM expression. RHAMM interacts intracellularly with interphase microtubules, centrosomes and the mitotic spindle apparatus, and its expression might therefore reflect the proliferative capacity of cells. Mohapatra et al. 22 and later Maxwell et al. 23 showed that both surface and intracellular forms of RHAMM are required for progression of cells through the cell cycle. In functional experiments, RHAMM-specific antibodies that block its function were injected into HeLa cells that resulted in cell cycle arrest in the G2/M phase. 22 In more detailed analyses, exon 4 of RHAMM was reported to be involved in the formation of the mitotic spindle apparatus. 23 Defective expression of the RHAMM Àexon4 splicing variant correlated with chromosomal instability and was found to be of negative prognostic value in patients with multiple myeloma. 18 In this study on B-CLL, levels of both the splicing variants of RHAMM were increased in IgVH unmutated as well as mutated cases. Therefore, in CLL the ratio of RHAMM Àexon4 /RHAMM FL was not of prognostic value. However, for RHAMM FL but not for RHAMM
Àexon4
, an increase during mitosis was reported. 18, 23 The elevated levels of both splicing variants of RHAMM might therefore reflect the proliferative potential of CLL cells. CLL cells from the PB are usually arrested in G0/G1 phase of the cell cycle. However, in the BM as well as in LNs, these cells may undergo rapid cell divisions. 14, 24 In line with this difference in proliferation in different tissues of CLL patients, we found elevated levels of RHAMM in BM as well as in LNs compared with PB CLL cells. Moreover, we observed a correlation between the expression of RHAMM and the proliferation marker Ki-67 and CD40L in the LNs of CLL patients. As CD40L has been described to be a factor that drives CLL cells into proliferation in vitro, 14, 17 we asked whether RHAMM may be a target of CD40L in CLL cells. To this end, we stimulated CLL cells with CD40L and measured expression of RHAMM. In line with a functional connection between CD40L, RHAMM and proliferation, we found an increased expression of RHAMM in CLL cells after stimulation with CD40L. This increase in the expression of RHAMM was much stronger when compared with the increase after stimulation with IL-4 and CpG, which induce the proliferation of CD40L independently. This finding suggests that RHAMM is a possible downstream target of CD40L.
Therefore, RHAMM, which we had identified as a LAA, is a marker associated with CD40L signaling as well as proliferation in CLL cells. In line with the concept of a high proliferative index as being associated with bad prognosis, we found that expression of RHAMM, which is connected with proliferation, is also significantly associated with TFS in CLL.
Earlier, we characterized RHAMM as TAA in several hematological malignancies. [2] [3] [4] Immunogenic TAA might elicit immune response against tumor targets and therefore slow disease progression. We found that patients with higher numbers of RHAMM-specific T cells tended to have longer TFS. This suggests that LAA-specific T cells in B-CLL patients might be able to attenuate progression of the disease. Moreover, we observed superior lysis of CLL cells by RHAMM-specific T cells when compared with specific lysis of T2 target cells bearing RHAMM-derived epitope. This effective lysis suggests that RHAMM might represent a target for immunotherapy of CLL patients. A potential hurdle for future immunotherapy might be the excess of Treg cells expressing FOXP3 in B-CLL. Treg cells have a strong potential to inhibit T-cell responses, including LAA-specific immune responses. In line with that, we noted an inverse correlation between the frequencies of Treg cells and RHAMM-specific CD8 þ T cells. In summary, evaluating the expression of RHAMM and its splicing variants in 72 CLL patients, we found increased levels of RHAMM, RHAMM FL and RHAMM Àexon4 in unmutated CLL cases that correlated with shorter TFS. The evaluation of RHAMM expression provided additional prognostic information for CLL patients. We found increased RHAMM expression in infiltrated LN from patients who also showed increased levels of the proliferation marker Ki-67 as well as CD40L. Moreover, we observed that expression of RHAMM is induced by stimulation with CD40L. Thus, expression levels of RHAMM might reflect the proliferative potential of CLL cells. Targeting the proliferating cell compartment might be beneficial for CLL patients. To this end, we found effective lytic activity of RHAMM-specific T cells isolated from CLL patients that were stimulated in vitro. Therefore, we suggest that RHAMM represents an interesting target for immunotherapy for B-CLL patients, especially for those with unfavorable prognostic markers.
